Testing effectiveness (Phase 2)Study completedNCT03625323
What this trial is testing
Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC
Who this might be right for
NSCLCHNSCC
Immutep S.A.S. 187